Procedure-related techniques and care pathways from the optimize pro clinical study show promising early outcomes for patients implanted with the medtronic evolut™ tavr system

Dublin, april 28, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced results from an interim analysis of the first 171 patients (including 71 roll-ins) treated in the optimize pro clinical study. the post-market, prospective, multi-center study is evaluating procedural outcomes (including pacemaker rate) associated with procedure-related techniques and post-procedure tavr care pathways when using the self-expanding, supra-annular evolut™ pro and pro+ tavr systems in patients with symptomatic severe aortic stenosis.
MDT Ratings Summary
MDT Quant Ranking